MammoRisk®, a scoring tool :

The risk model used by MammoRisk is based on the evaluation, from a database of individuals tracked over time, of the risks of an individual compared to the future of his “closest” neighbors.

The proprietary and innovative “Nearest Neighbors” approach uses data-mining and statistics to assess an individual’s risk of developing a serious pathology.

This method aims to evaluate, on a number of people said to be neighbors (same characteristics: age, family history …), how many of them are likely to develop an illness. This makes it possible to evaluate the risks of an individual in comparison with his “closest” neighbors. This flexible method can adapt to all databases and replace complex and opaque mathematical models used until then. This innovative approach to calculating risk has been patented.

Applied to breast cancer, it is also validated from French and American organized screening data, in collaboration with several screening organizations.

The MammoRisk® score was develloped and validated on the basis of breast cancer cohorts:

  • 1 million women in the United-States of America between 40 and 74 years-old.
  • 350,000 women in France between 50 and 74 years-old.

MammoRisk®, a test that integrates the 3 fundamental breast cancer risk factors :

Breast Density:

Women with a high degree of breast density have a higher risk of breast cancer. Women with a higher density have a 4 to 6 times greater risk of breast cancer than women whose breasts are almost entirely made up of adipose tissue.

Breast density decreases with age, but certain breast cancer risk factors are also linked to breast density. Breast density is higher in women with no children, or those who had their first pregnancy late, or those who consume more alcohol or have a high body mass index (post-menopause).

DenseeMammo, (is a software developed by Predilife), allows an automatic evaluation of breast density from a mammography.

Polygenic score (PRS)

PRS is the result of a genetic test. PRS results from the combination of several SNPs (Single Nucleotide Polymorphisms) in a polygenic risk score. While the risk associated with an individual SNP is low, combining multiple SNPs into a polygenic risk score increases the power of the association. PRS are statistically independent of established clinical risk factors.

The complementarity of SNPs to predict the risk of breast cancer, compared to other risk factors for breast cancer such as breast density or reproductive history is now demonstrated. Combinations of risk models including conventional clinical variables + breast density + PRS are used to more accurately estimate population risk. This helps to refine and better discriminate between high and low risk groups

Clinical data questionnaire:

Family history:

The existence of a family history of breast cancer is one of the main risk factors for breast cancer, especially if those cases of breast cancer were diagnosed when the family members were still young. Around 20-30% of breast cancers appear in women with a family history of breast cancer, in other words several cases of breast cancer within the same family.

Patiente age:

Breast cancer is the most common cancer found in women in France, across the European Union and in the United-States. The number of cases diagnosed each year has tended to decline since 2005, even though this particular disease remained the main cause of death for women diagnosed with cancer in 2012. If it is detected at an early stage, this cancer can be cured in 9 out of 10 cases.

Previous biopsy:

Personnal history of breast biopsy are associated with an increased risk of breast cancer. But the reality is that biopsy is not a risk factor itself, but it should rather be a marker of risk. That examination can be realized in case of suspicion of an anomaly or a lesion at the level of the breast.

The MammoRisk® test :



What result?

At the end of the test, MammoRisk® provide a clear and precise report with an estimate of the absolute 5 years risk of cancer, that is to say, the probability of developing an invasive cancer during a interval 5 years.

From this estimation, the doctor and the patient will take a joint decision, regarding a personalized screening program

MammoRisk® allows you to edit a complete report,including:

  • The different risk factors taken into account
  • The breast density estimated by DenSeeMammo (if combine use)
  • The breast cancer risk estimation with an illustration
  •  A personalized screening